Steven Julious
banner
stevenjulious.bsky.social
Steven Julious
@stevenjulious.bsky.social
Professor of Medical Statistics, walker and Garibaldi Red
Pinned
Had a paper published with Kelly Grant on the analysis of recurrent events in clinical trials

We recommend that the conditional frailty model be used for these data trials, including cluster randomised trials, to help explain changes in event risk over time, and assist clinical interpretation
Reposted by Steven Julious
The first 12 months of our project evaluating same-day emergency care (SDEC) is nearly over.

You can read about how the project is progressing on our website:

sites.google.com/sheffield.ac...

@fohsheffield.bsky.social @scharr-msg.bsky.social @arc-yharc.bsky.social

#SDEC #NHS #NIHR
SDEC
Latest project news
sites.google.com
October 16, 2025 at 4:51 PM
Reposted by Steven Julious
Our PhD student is looking for children aged 5-16 with asthma in the UK to complete a survey to better understand inhaler use during the summer holidays among children and adolescents with asthma:
shef.qualtrics.com/jfe/form/SV_...

Please forward on.
@stevenjulious.bsky.social
Summer Holidays Inhaler Use
The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.
shef.qualtrics.com
September 3, 2025 at 1:18 PM
Had a paper published with Laura Flight and @alan-brennan.bsky.social entitled

Value-adaptive clinical trial designs for efficient delivery of publicly funded trials - a discussion of methods, case studies, opportunities and challenges

doi.org/10.1186/s128...
Value-adaptive clinical trial designs for efficient delivery of publicly funded trials - a discussion of methods, case studies, opportunities and challenges - BMC Medical Research Methodology
Background Value-adaptive designs for clinical trials are a novel set of emerging methods for delivering greater value for clinical research. There is increasing interest in using them within publicly...
doi.org
June 9, 2025 at 8:17 AM
Reposted by Steven Julious
Next Thursday, June 5th at 1pm (BST) we host our 4th webinar in our adverse event special series. Rayan Taher & Jenny Yiend will present their work on developing a process for assessing the safety of a digital mental health intervention & gaining regulatory approval. Register here: lnkd.in/eaW3MQrB
Microsoft Forms
forms.microsoft.com
May 28, 2025 at 9:43 AM
The protocol for MissionEB - a randomised, double-blinded, placebo-controlled, two-centre, crossover trial - a study to assess mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa has just published

doi.org/10.1136/bmjo...
Mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: MissionEB protocol for a randomised, double-blinded, placebo-controlled, two-centre, crossov...
Introduction Recessive dystrophic epidermolysis bullosa (RDEB) is a severe genetic mucocutaneous fragility disorder characterised by chronic blistering, slow wound healing and increased risk of squamo...
doi.org
May 27, 2025 at 8:57 AM
A great talk at #SCT2025 by James Salsbury entitled

Assurance methods for designing a survival trial with delayed treatment effects
May 21, 2025 at 4:29 PM
Attending an excellent talk by Nikki Totton at #SCT2025 entitled

Using benefit risk methods to adjust the non-inferiority margin based on treatment benefits
May 21, 2025 at 4:27 PM
Reposted by Steven Julious
In clinical trials it is not only potential benefits that should be measured - it is crucially important that any potential #harms are also investigated 1/7
#MethodologyMonday #118
May 19, 2025 at 6:12 AM
Had a paper published with Kelly Grant on the analysis of recurrent events in clinical trials

We recommend that the conditional frailty model be used for these data trials, including cluster randomised trials, to help explain changes in event risk over time, and assist clinical interpretation
May 20, 2025 at 2:50 PM
Reposted by Steven Julious
Comparison of statistical methods for the analysis of patient-reported outcomes (PROs), particularly the Short-Form 36 (SF-36), in randomised controlled trials (RCTs) using standardised effect size (SES): an empirical analysis

hqlo.biomedcentral.com/articles/10....
Comparison of statistical methods for the analysis of patient-reported outcomes (PROs), particularly the Short-Form 36 (SF-36), in randomised controlled trials (RCTs) using standardised effect size (S...
Background The Short-Form 36 (SF-36), a widely used patient-reported outcome (PRO), is a questionnaire completed by patients measuring health outcomes in clinical trials. The PRO scores can be discret...
hqlo.biomedcentral.com
April 29, 2025 at 7:27 PM
Reposted by Steven Julious
Second paper from the prosec3 study: Further development of a patient-reported outcome measure to assess the impact of oral secretion problems in people living with MND www.tandfonline.com/doi/full/10....
Further development of a patient-reported outcome measure to assess the impact of oral secretion problems in people living with MND
Objective: Oral secretion problems are common yet poorly managed in people living with MND (plwMND). A validated patient-reported outcome for measuring saliva symptoms in this patient group would f...
www.tandfonline.com
March 11, 2025 at 10:26 AM
Reposted by Steven Julious
New paper!! Estimating the minimum important difference in the ALSFRS-R-instrument in people living with MND www.tandfonline.com/doi/full/10....
Estimating the minimum important difference in the ALSFRS-R-instrument in people living with MND
Objective: The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) is a commonly used outcome measure in clinical trials for motor neuron disease (MND) therapies. As such, understandin...
www.tandfonline.com
February 10, 2025 at 9:18 AM
Today's date

5-2-25

Is a palindrome
February 5, 2025 at 2:32 PM
Reposted by Steven Julious